|
Tiotropium as Asthma Add-On Treatment Shows Promise
Monthly Prescribing Reference Boehringer Ingelheim has announced positive results from several Phase 3 studies analyzing once-daily tiotropium (Spiriva; Boehringer Ingelheim) delivered via the Respimat inhaler as an add-on treatment for asthma patients who remain symptomatic with … Phase III studies show tiotropium delivered via Respimat inhaler proves … |
View full post on asthma – Google News